Logo image of KMPH

KEMPHARM INC (KMPH) Stock Fundamental Analysis

USA - NASDAQ:KMPH - US4884452065 - Common Stock

5.81 USD
-0.02 (-0.34%)
Last: 2/28/2023, 8:00:03 PM
Fundamental Rating

2

KMPH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. While KMPH seems to be doing ok healthwise, there are quite some concerns on its profitability. KMPH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KMPH had negative earnings in the past year.
In the past year KMPH has reported a negative cash flow from operations.
KMPH Yearly Net Income VS EBIT VS OCF VS FCFKMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -20M -40M -60M

1.2 Ratios

The profitability ratios for KMPH are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KMPH Yearly ROA, ROE, ROICKMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KMPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KMPH Yearly Profit, Operating, Gross MarginsKMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -50 -100 -150 -200

More info and screens

5

2. Health

2.1 Basic Checks

KMPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
KMPH has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, KMPH has an improved debt to assets ratio.
KMPH Yearly Shares OutstandingKMPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M
KMPH Yearly Total Debt VS Total AssetsKMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of 1.51, we must say that KMPH is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of KMPH (1.51) is better than 65.16% of its industry peers.
KMPH has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.14, KMPH is in line with its industry, outperforming 42.99% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 1.51
ROIC/WACCN/A
WACC8.07%
KMPH Yearly LT Debt VS Equity VS FCFKMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 10.10 indicates that KMPH has no problem at all paying its short term obligations.
KMPH's Current ratio of 10.10 is amongst the best of the industry. KMPH outperforms 82.35% of its industry peers.
A Quick Ratio of 10.10 indicates that KMPH has no problem at all paying its short term obligations.
KMPH has a Quick ratio of 10.10. This is amongst the best in the industry. KMPH outperforms 82.35% of its industry peers.
Industry RankSector Rank
Current Ratio 10.1
Quick Ratio 10.1
KMPH Yearly Current Assets VS Current LiabilitesKMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

KMPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.83%, which is quite impressive.
Looking at the last year, KMPH shows a very negative growth in Revenue. The Revenue has decreased by -62.30% in the last year.
EPS 1Y (TTM)64.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-280%
Revenue 1Y (TTM)-62.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%46.26%

3.2 Future

KMPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.57% yearly.
KMPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.23% yearly.
EPS Next Y-143.91%
EPS Next 2Y-23.09%
EPS Next 3Y14.78%
EPS Next 5Y37.57%
Revenue Next Year-59.96%
Revenue Next 2Y-19.37%
Revenue Next 3Y11.18%
Revenue Next 5Y29.23%

3.3 Evolution

KMPH Yearly Revenue VS EstimatesKMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
KMPH Yearly EPS VS EstimatesKMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KMPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KMPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KMPH Price Earnings VS Forward Price EarningsKMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KMPH Per share dataKMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

KMPH's earnings are expected to grow with 14.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.09%
EPS Next 3Y14.78%

More info and screens

0

5. Dividend

5.1 Amount

KMPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KEMPHARM INC

NASDAQ:KMPH (2/28/2023, 8:00:03 PM)

5.81

-0.02 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-09 2022-11-09/amc
Earnings (Next)03-28 2023-03-28/bmo
Inst Owners83.06%
Inst Owner Change6.66%
Ins Owners21.5%
Ins Owner Change0%
Market Cap200.47M
Analysts84.44
Price Target22.78 (292.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.26%
Min EPS beat(2)-55.23%
Max EPS beat(2)-43.29%
EPS beat(4)1
Avg EPS beat(4)-23.05%
Min EPS beat(4)-55.23%
Max EPS beat(4)10.87%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-20.57%
Min Revenue beat(2)-29.19%
Max Revenue beat(2)-11.95%
Revenue beat(4)2
Avg Revenue beat(4)-0.26%
Min Revenue beat(4)-29.19%
Max Revenue beat(4)26.84%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.7
P/FCF N/A
P/OCF N/A
P/B 2.14
P/tB 2.14
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.31
BVpS2.72
TBVpS2.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.1
Quick Ratio 10.1
Altman-Z 1.51
F-Score2
WACC8.07%
ROIC/WACCN/A
Cap/Depr(3y)20.27%
Cap/Depr(5y)24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-280%
EPS Next Y-143.91%
EPS Next 2Y-23.09%
EPS Next 3Y14.78%
EPS Next 5Y37.57%
Revenue 1Y (TTM)-62.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%46.26%
Revenue Next Year-59.96%
Revenue Next 2Y-19.37%
Revenue Next 3Y11.18%
Revenue Next 5Y29.23%
EBIT growth 1Y-350.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-586.19%
EBIT Next 3Y-64.71%
EBIT Next 5Y46.24%
FCF growth 1Y-279.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-279.47%
OCF growth 3YN/A
OCF growth 5YN/A